TherapeuticsMD (TXMD) Gets a Buy Rating from H.C. Wainwright

By Carrie Williams

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on TherapeuticsMD (TXMDResearch Report), with a price target of $7.00. The company’s shares closed last Monday at $2.85.

According to, Tsao is a 1-star analyst with an average return of -1.9% and a 46.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Outlook Therapeutics Inc, and Protagonist Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for TherapeuticsMD with a $11.80 average price target, implying a 312.6% upside from current levels. In a report issued on October 25, Stifel Nicolaus also maintained a Buy rating on the stock with a $17.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.09 and a one-year low of $1.82. Currently, TherapeuticsMD has an average volume of 3.5M.

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TXMD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.